Cardiomyopathy, amyloidosis
These companies develop drugs for hypertrophic cardiomyopathy and transthyretin amyloidosis.
−42.1%
over 1 year · S&P 500 +11.6%
Key indicators
Health
50 / 100
Fragile
Solid
Up over 1 year
4 of 7
Volatility
54%
Calm
Choppy
Profitability
−111%
Low
High
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 8 companies
ALNY
−63.5%
BBIO
+18.2%
Size: weight in the tag. Color: move over the period.